Bangladesh's pharmaceutical industry still remains a fundamental part of the country's manufacturing economy, displaying notable resilience and competition trends. According to the most recent data available in IQVIA MAT Q1, 2026, the total value of the market is a noteworthy 39,535 Crore BDT, registering a year-on-year growth rate of 7.9% and a robust 4-year CAGR of 10.9%.
1. The Undisputed Leaders: Top 5 Market Shakers
There is a small cluster of leading domestic producers that retain control over the largest chunk of the market. The share of the top five producers represents 52% of all pharmaceutical production in Bangladesh.
SQUARE Pharmaceuticals:
Retaining its traditionally leading position, SQUARE retains the 16.9% market share and 6,693 Crore BDT valuation. The company’s growth rate declined marginally to 3.9%, but the 4-year CAGR still stands at 8.8%.
INCEPTA PHARMA:
Taking the second place, Incepta shares the 12.5% market share and 4,948 Crore BDT valuation. It exceeded the market average growth by 7.3% and enjoys quite a robust 4-year CAGR of 13.4%.
BEXIMCO:
Coming in third with 3,847 Crore BDT (9.7% market share), Beximco showed a strong double-digit growth of 11.3%.
HEALTHCARE PHARMA:
Still retaining its fourth place, Healthcare Pharma has 7.4% of the market share, which equals 2,925 Crore BDT.
RENATA:
Completing the top five ranking, Renata obtained 2,258 Crore BDT (5.7% market share) along with the same dynamics as Beximco, 10.0%.
2. High-Growth Champions and Rising Stars
Beyond the immediate market leaders, several manufacturers are exhibiting extraordinary momentum, radically outpacing the baseline market growth of 7.9%.
The 20%+ Growth Club
- SUN PHARMA (Rank 21): Spurred the highest single-period growth in the entire top 30 list, skyrocketing by 36.9% to hit 321 Crore BDT.
- ZISKA (Rank 16): Achieved a stellar 23.3% growth rate, bringing its valuation to 461 Crore BDT.
- RADIANT PHARMA (Rank 10): Broke into the top ten with an exceptional 21.2% growth, valued at 1,557 Crore BDT.
- ARISTOPHARMA (Rank 7): Continues to pull significant weight with a 20.0% growth rate and a commanding 16.9% 4-year CAGR.
Long-Term Value Drivers (4-Year CAGR)
When looking at long-term sustainability, POPULAR PHARMA (Rank 9) leads the pack with an outstanding 23.5% 4-year CAGR, followed closely by NAVANA (Rank 22) at 17.7%.
3. Market Share Distribution: At a Glance
The following table summarizes the standings and performance metrics of the top 15 manufacturers in Bangladesh, as detailed in image_65b9ab.jpg:
| Rank | Manufacturer | Value (Crore BDT) | Market Share (%) | Growth (%) | CAGR% (4 Years) |
| — | TOTAL MARKET | 39,535 | 100.0 | 7.9 | 10.9 |
| 1 | SQUARE | 6,693 | 16.9 | 3.9 | 8.8 |
| 2 | INCEPTA PHARMA | 4,948 | 12.5 | 7.3 | 13.4 |
| 3 | BEXIMCO | 3,847 | 9.7 | 11.3 | 13.0 |
| 4 | HEALTHCARE PHARMA | 2,925 | 7.4 | 4.7 | 12.3 |
| 5 | RENATA | 2,258 | 5.7 | 10.0 | 13.1 |
| 6 | ESKAYEF | 1,935 | 4.9 | 11.0 | 14.9 |
| 7 | ARISTOPHARMA | 1,872 | 4.7 | 20.0 | 16.9 |
| 8 | OPSONIN PHARMA | 1,834 | 4.6 | 6.0 | 9.8 |
| 9 | POPULAR PHARMA | 1,601 | 4.1 | 7.0 | 23.5 |
| 10 | RADIANT PHARMA | 1,557 | 3.9 | 21.2 | 13.3 |
| 11 | ACME | 1,548 | 3.9 | 9.2 | 12.9 |
| 12 | A.C.I. | 1,485 | 3.8 | 11.5 | 12.7 |
| 13 | DRUG INTERNATIONAL | 1,182 | 3.0 | 17.5 | 7.9 |
| 14 | UNIMED & UNIHEALTH | 891 | 2.3 | 1.3 | 8.4 |
| 15 | BEACON PHARMA | 543 | 1.4 | 6.3 | 10.9 |
4. Notable Market Contractions
While the broader sector is expanding, several companies faced significant downward adjustments during this period, signaling shifting consumer preferences or operational hurdles.
- GENERAL (Rank 29): Suffered the sharpest decline in the report, with market value contracting by -75.3% and a long-term CAGR drop of -37.6%.
- ORION PHARMA LTD. (Rank 26): Registered a double-digit decline of -14.1%, dropping its value to 188 Crore BDT.
- NEVIAN LIFESCI. (Rank 24): Slumped by -8.0% over the year.
- MNC Presence: Multinationals like NOVO NORDISK (Rank 17) stayed relatively flat with a minor 0.1% growth and a negative 4-year CAGR of -2.1%, showcasing how aggressively local manufacturers are capturing the domestic market space.
Key Takeaways for Industry Stakeholders
The IQVIA MAT Q1 2026 figures show that there exists a strong ecosystem in which local capability has become sophisticated enough to call the shots. While leading giants like SQUARE and Incepta continue holding their competitive moats, the double-digit growth shown by mid-sized firms like Radiant, Sun, and Aristopharma clearly shows that there is enough scope for innovation.
Investors as well as supply chain managers would need to focus on these high-growth anomalies to understand where the next wave of therapeutic expansion will take place in Bangladesh.
Do you want to go into greater detail about therapeutic categories, or do you want me to discuss macroeconomic factors such as API importing?